This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Why Is Chemed (CHE) Up 7.7% Since Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Chemed (CHE) witnesses balanced segmental growth in third-quarter 2019.
Chemed (CHE) Q3 Earnings Beat Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 4.53% and -0.89%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stock Earnings Slated on Oct 29: HCA, MOH & More
by Zacks Equity Research
Increasing demands for products and services are likely to have driven earnings for players in the healthcare industry.
Here's Why You Should Hold on to Chemed (CHE) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed's (CHE) performance.
Zacks.com featured highlights include: MDU Resources, Gibraltar Industries, Chemed, Federal Signal and SolarEdge Technologies
by Zacks Equity Research
Zacks.com featured highlights include: MDU Resources, Gibraltar Industries, Chemed, Federal Signal and SolarEdge Technologies
Buy These 5 Low Leverage Stocks to Stay Afloat in Crisis
by Zacks Equity Research
With Q3 reporting season knocking on the door, investors are eyeing stocks that exhibited solid earnings growth in the prior quarters. But one should consider the stocks' debt levels before investing.
5 Defensive Stocks to Guard Against Economic Slow Down
by Zacks Equity Research
U.S. GDP growth estimate has slowed to 2% with trade war impacting exports and business investment. Investors should look for safer options in the form of defensive stocks.
The Zacks Analyst Blog Highlights: AquaVenture, Chemed, Materion, Clean Harbors and Crocs
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AquaVenture, Chemed, Materion, Clean Harbors and Crocs
A Third Rate Cut Hinges on Interim Trade Deal: Likely Gainers
by Nalak Das
Trade dispute between the United States and China is the primary source of global economic disturbance. Possibility of a third rate cut depends on the reality of an interim trade deal.
The Zacks Analyst Blog Highlights: AquaVenture, MDU Resources, Safehold, Industrial Logistics Properties Trust and Chemed
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AquaVenture, MDU Resources, Safehold, Industrial Logistics Properties Trust and Chemed
Buy These 5 Low Leverage Stocks if You Want to Avoid Risk
by Zacks Equity Research
Statistically, companies prefer debt over equity since debt is easily available and cheaper than equity. Yet, debt ridden companies are more prone to bankruptcy in times of crisis.
Fed May Cut Rate Again Despite Stable Economy: 5 Picks
by Nalak Das
Global economic slowdown is the major concern of Fed. The European Central Bank recently injected stimulus like rate cut and quantitative easing to restore growth in the Eurozone economy.
The Zacks Analyst Blog Highlights: Exantas, Chemed, Viad, Arbor Realty and DaVita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exantas, Chemed, Viad, Arbor Realty and DaVita
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed's (CHE) performance.
Strong ISM Services Index Eases Recession Fears: 5 Top Picks
by Nalak Das
The ISM Services index clearly reflects that the U.S. economy has sustained its momentum despite heightened trade conflict and global economic slowdown.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Up 13.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Looking for a Growth Stock? 3 Reasons Why Chemed (CHE) is a Solid Choice
by Zacks Equity Research
Chemed (CHE) possesses solid growth attributes, which could help it handily outperform the market.
Will Powell Hint Lead to Global Rate Cuts? Likely Gainers
by Nalak Das
Powell's lecture gets huge importance in view of the recent global trend of rate cut to combat the economic slowdown by several major central banks.
Outlook for Outpatient and Home Healthcare Industry Looks Bright
by Trina Mukherjee
Growth prospects look bright for the Zacks Outpatient and Home Healthcare industry, thanks to AI, cost effectiveness and rise in demand of drug rehabilitation centers.
The Zacks Analyst Blog Highlights: Alamos Gold, Chemed, Safehold, Franco-Nevada and DaVita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alamos Gold, Chemed, Safehold, Franco-Nevada and DaVita